FDA approves 'potential blockbuster' migraine jab from Lundb...

The FDA has approved Lundbeck’s eptinezumab prophylactic treatment for migraine, the last from a gang of four drugs from a new class.

Roche and Lilly's Alzheimer's drugs draw blanks in inherited...

As Biogen prepares for an FDA review of its amyloid-targeting Alzheimer’s drug aducanumab, Roche and Eli Lilly lifted the lid on yet another trial failure involving two drugs aimed at this

Ozempic acceleration buoys Novo Nordisk, and threatens Lilly

Lilly’s diabetes med Trulicity shrugs off Novo Nordisk chall...

Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but the most pleasing aspect for the firm was likely the resilience of its diabetes blockbus

Lilly keeps ahead of Blueprint with swift FDA review for sel...

Lilly, Boehringer bag FDA okay for diabetes triple Trijardy ...